Navigation Links
Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
Date:10/14/2008

ing diseases. In addition to a recently completed Phase IIIb study in malignant mesothelioma, Alfacell is currently planning for Phase II clinical trials in other oncology indications. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainty whether the clinical trial results will allow the company to complete submission of a New Drug Application and if a New Drug Application submission is completed, uncertainty whether FDA will file or approve such application, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials or differences of opinion in interpreting the results of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

ALFACELL CORPORATION

Condensed Statements of Operations

Three-Months Ended Fiscal Year Ended

July 31 July 31

2008 2007 2008
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
2. Alfacell Hires Advisors to Advance Strategic Alternatives
3. Alfacell Receives NASDAQ Delisting Letter
4. Alfacell Receives NASDAQ Non-Compliance Notification
5. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
6. Alfacell Announces Retirement of Chief Executive Officer
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
11. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... YORK , July 28, 2014  David ... ConvergeHEALTH by Deloitte , has been elected ... Interchange Standards Consortium, a non-profit working to establish ... data, particularly as it relates to electronic health ... continue CDISC,s mission of collaborating with organizations across ...
(Date:7/28/2014)... July 28, 2014 It’s a hard truth: ... benefits to further their post-secondary education are failing to obtain ... released this year. And according to an analysis by ... is veteran students’ uninformed choice of college majors, which leads ... of the study: Some 51.7 percent of post-9/11 veterans using ...
(Date:7/28/2014)... DUBLIN , July 28, 2014 Research ... "Global Particle Size Analysis Market 2014-2018" report to their ... Particle size analysis is a technique used to determine ... powder or liquid. It is crucial to analyze the size ... material. Therefore, particle size analysis is performed to determine the ...
(Date:7/25/2014)... 25, 2014 Amgen (NASDAQ: AMGN ... a $0.61 per share dividend for the third quarter ... 5, 2014, to all stockholders of record as of ... About Amgen Amgen is committed to unlocking ... illnesses by discovering, developing, manufacturing and delivering innovative human ...
Breaking Biology Technology:ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Global Particle Size Analysis Market 2014-2018 2Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3
... today announced the receipt of a two-year Small Business ... the National Institute on Aging, National Institutes of Health ... antibodies targeting tau protein oligomers in the development of ... be screened at the Michigan High Throughput Screening Center ...
... Wound Management Technologies, Inc., (OTC Bulletin Board: ... solutions, announced today that its President, Deborah Jenkins Hutchinson, ... product, CellerateRX®, recent strategic developments, and its product pipeline ... be held at the JW Marriott Marquis Miami on ...
... a way to overcome one of the main limitations of ... Everyone who has had an ultrasound, including most pregnant women, ... of the limits to the detail obtainable with sonography is ... dictate that the smallest objects you can "see" are about ...
Cached Biology Technology:Oligomerix, Inc. Awarded Phase II NIH Grant to Discover Novel Drugs for Alzheimer's Disease 2Wound Management Technologies to Present at LifeTech Capital Miami Medical Investors Conference 2Novel metamaterial vastly improves quality of ultrasound imaging 2
(Date:7/27/2014)... In one of the largest prevalence studies to date, ... genotype prevalence estimates for the hepatitis C virus (HCV). ... Association for the Study of Liver Diseases, indicate that ... 83 million patients infected of which one-third reside in ... cases, is the next most prevalent, followed by genotypes ...
(Date:7/27/2014)... RESEARCH UK scientists at Barts Cancer Institute have found ... cancer therapy significantly more effective, according to research published ... Barts Cancer Institute, part of Queen Mary University of ... kinase (FAK), signals the body to repair itself after ... DNA. When the researchers removed FAK from blood vessels ...
(Date:7/25/2014)... Before the colonial era, 100,000s of people lived on ... cultures manipulated fire to control the availability of plants ... tribes continue to use fire to maintain desired habitat ... the U.S. Forest Service,s Pacific Southwest Station, will lead ... National Wildfire Refuge during the Ecological Society of America,s ...
Breaking Biology News(10 mins):Hepatitis C virus genotype 1 is most prevalent worldwide 2New drug target can break down cancer's barrier against treatment 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... the University of Maryland Center for Environmental Science ... a lack of predators and competitors was the ... dogfish observed in Southern New Englands Georges Bank ... 1980s. In an article appearing in the ...
... a new environment while others do not" Scientists from ... headway on this question after analyzing how fast cane ... 70 years of data on toad presences collected since ... regions of Australia at dramatically divergent rates. These variable ...
... Arenas, Chile, on the tip of South America, to spend ... Southern Ocean. Here they hope to make groundbreaking measurements to ... and sea, and vice-versa. The cruise, ... the greenhouse gas carbon dioxide moves between the ocean and ...
Cached Biology News:Researchers offer new theory for dogfish and skate population outburst on George's Bank 2Voyage to Southern Ocean aims to study air-sea fluxes of greenhouse gases 2